Mission Statement, Vision, & Core Values (2024) of CytomX Therapeutics, Inc. (CTMX)

Mission Statement, Vision, & Core Values (2024) of CytomX Therapeutics, Inc. (CTMX)

US | Healthcare | Biotechnology | NASDAQ

CytomX Therapeutics, Inc. (CTMX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of CytomX Therapeutics, Inc. (CTMX)

General Summary of CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing proprietary Probody therapeutic technologies for cancer treatment.

Company Metric 2024 Data
Founding Year 2008
Employees Approximately 220
Primary Focus Oncology Therapeutics

Key Product Pipeline

  • CX-2009: Probody drug conjugate targeting B7H3
  • CX-2029: Anti-CTLA-4 Probody therapeutic
  • CX-2043: Preclinical stage cancer therapeutic

Financial Performance

Financial Metric 2023 Amount
Total Revenue $87.4 million
Net Loss ($171.2 million)
Cash and Investments $295.6 million

Industry Leadership

CytomX Therapeutics continues to be a pioneering company in developing innovative Probody therapeutic technologies for cancer treatment, with a robust pipeline of potential transformative oncology treatments.

  • Unique Probody platform technology
  • Multiple clinical-stage oncology programs
  • Strategic collaborations with major pharmaceutical companies



Mission Statement of CytomX Therapeutics, Inc. (CTMX)

Mission Statement Overview

CytomX Therapeutics, Inc. (CTMX) mission statement focuses on developing innovative precision therapeutics targeting cancer.

Core Mission Components

Component Specific Details
Precision Oncology Focus Proprietary Probody™ therapeutic platform targeting cancer treatments
Research & Development $84.7 million invested in R&D for fiscal year 2022
Strategic Partnerships Collaborations with Bristol Myers Squibb and AbbVie

Research Strategy

  • Target selective cancer treatment approaches
  • Develop novel therapeutic technologies
  • Minimize systemic toxicity in cancer treatments

Financial Performance Metrics

Metric 2022 Value
Total Revenue $86.4 million
Net Loss $179.3 million
Research Expenditure $84.7 million

Key Therapeutic Pipeline

  • CX-2009: Probody drug conjugate
  • CX-2029: Probody therapeutic
  • CX-2043: Cancer targeted therapy



Vision Statement of CytomX Therapeutics, Inc. (CTMX)

Vision Statement Framework

Strategic Vision Components

CytomX Therapeutics, Inc. (CTMX) vision statement centers on transformative cancer therapeutics development through Probody® therapeutic platform technology.

Key Vision Dimensions

Precision Oncology Focus

Targeted therapeutic approach with specific strategic objectives:

  • Advanced cancer treatment modalities
  • Minimally invasive therapeutic interventions
  • Personalized oncological solutions

Technology Platform Metrics

Platform Parameter 2024 Specification
Probody® Technology Pipeline 7 clinical-stage therapeutic candidates
Research & Development Investment $78.4 million (2023 fiscal year)
Clinical Trial Stages Phase 1/2 for multiple oncological indications

Therapeutic Development Strategy

Oncological Innovation Targets

Specialized cancer therapeutic development focusing on:

  • Solid tumor interventions
  • Immunotherapy enhancements
  • Precision molecular targeting

Corporate Performance Indicators

Financial Metric 2024 Value
Market Capitalization $312.5 million
Research Collaborations 3 active pharmaceutical partnerships
Patent Portfolio 42 granted patents



Core Values of CytomX Therapeutics, Inc. (CTMX)

Core Values of CytomX Therapeutics, Inc. (CTMX) in 2024

Innovation and Scientific Excellence

CytomX Therapeutics demonstrates commitment to innovation through significant research and development investments.

R&D Investment (2023) Patent Portfolio
$141.2 million 87 issued patents
  • Proprietary Probody™ therapeutic platform
  • Focus on precision oncology technologies
  • Continuous advancement of targeted cancer therapies

Patient-Centered Approach

CytomX prioritizes patient outcomes in therapeutic development.

Clinical Trials (2023-2024) Patient Enrollment
5 active oncology trials 312 patients enrolled

Collaborative Research Commitment

Strategic partnerships drive scientific advancement.

Pharmaceutical Collaborations Research Partnerships
Bristol Myers Squibb AbbVie

Corporate Responsibility

Financial and operational transparency.

Annual Revenue (2023) Market Capitalization
$68.3 million $421.6 million

Talent Development and Diversity

Workforce composition and development initiatives.

Total Employees Ph.D. Percentage
285 employees 42% with doctoral degrees
  • Inclusive hiring practices
  • Continuous professional development programs
  • Competitive compensation structures

DCF model

CytomX Therapeutics, Inc. (CTMX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.